STOCK TITAN
  1. Home
  2. Sec-filings
  3. EVAX
  4. [6-K] Evaxion A/S Current Report (Foreign Issuer)

Evaxion (NASDAQ: EVAX) sets August 20 call for Q2 2026 results and update

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Evaxion A/S, a clinical-stage TechBio company using its AI-Immunology™ platform to develop novel vaccines, plans to provide a business update and report its second quarter 2026 financial results on August 20, 2026 before the opening of the Nasdaq CM.

Executive management will host a conference call and webcast the same day at 14:30 CET / 08:30 EST to present the update and results and take questions. Participants must register in advance to receive dial-in details and may also access a live webcast, with a recording available on the company’s website.

Positive

  • None.

Negative

  • None.
Q2 2026 results date August 20, 2026 Date Evaxion will report second quarter 2026 financial results
Conference call time CET 14:30 CET Start time of Evaxion’s August 20, 2026 conference call
Conference call time EST 08:30 EST Corresponding U.S. Eastern time for the same call
Team size +40 Number of experts covering the value chain from target discovery to clinical development
TechBio technical
"Evaxion A/S, a clinical-stage TechBio company developing novel vaccines"
A techbio company uses advanced engineering, computing and data tools together with biology to design or make new medicines, diagnostics, or bio-based products. For investors, it signals a blend of lab science and software-style innovation: potential for rapid scaling and platform value but also higher research costs, longer development timelines, and technical risk—similar to backing an engineering-driven startup applied to living systems.
AI-Immunology™ technical
"developing novel vaccines with its pioneering AI-Immunology™ platform"
ai-immunology™ is the use of artificial intelligence techniques to analyze immune system data and guide the discovery, design and testing of immune-based diagnostics, vaccines and therapies. It matters to investors because it can speed up research, reduce costs and reveal promising drug targets that traditional methods might miss—like using a powerful search engine to find a few needles in a vast haystack of biological signals—potentially increasing the chance and pace of commercial returns.
forward-looking statements regulatory
"This announcement contains forward-looking statements within the meaning of Section 27A"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Annual Report on Form 20-F regulatory
"refer to the risk factors included in our most recent Annual Report on Form 20-F"
An annual report on Form 20-F is a standardized filing that foreign companies submit to the U.S. securities regulator to disclose their financial results, business operations, risks, and management’s discussion of performance. It matters to investors because it provides a complete, audited snapshot—like a company’s financial report card and shareholder letter combined—used to assess transparency, compare companies, and judge whether the stock’s price matches underlying business strengths and risks.

FAQ

When will Evaxion (EVAX) report its second quarter 2026 financial results?
Evaxion will report its second quarter 2026 financial results on August 20, 2026 before the opening of the Nasdaq CM, alongside a business update from executive management.

Will Evaxion (EVAX) host a call for the Q2 2026 results and business update?
Yes. Evaxion’s executive management will host a conference call and webcast on August 20, 2026 at 14:30 CET / 08:30 EST to discuss the business update and second quarter 2026 results.

How can investors join Evaxion’s (EVAX) Q2 2026 earnings conference call?
To join the call, investors must register in advance via the provided link to receive dial-in numbers and a unique PIN. The call opens 15 minutes before the 14:30 CET / 08:30 EST start time.

Will a replay of Evaxion’s (EVAX) Q2 2026 webcast be available?
Yes. A webcast recording of Evaxion’s August 20, 2026 business update and Q2 2026 results presentation will be made available on the company’s website shortly after the live event concludes.

What does Evaxion (EVAX) focus on with its AI-Immunology platform?
Evaxion focuses on using its AI-Immunology™ platform to decode the immune system and develop novel vaccine candidates for cancer and infectious diseases, including both personalized and off-the-shelf cancer vaccines and prophylactic vaccines.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2026

Commission File Number: 001-39950

Evaxion A/S
(Exact Name of Registrant as Specified in Its Charter)

Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]      Form 40-F [   ]

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Press Release

On August 14, 2026, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits  

Exhibit Number Description
   
99.1 Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

   Evaxion A/S
   (Registrant)
    
   
Date: August 14, 2026 By:/s/ Helen Tayton-Martin    
   Helen Tayton-Martin
   Chief Executive Officer
   

EXHIBIT 99.1

Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026

COPENHAGEN, Denmark, August 14, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its second quarter 2026 financial results on Thursday August 20, 2026, before opening of the Nasdaq CM.

Evaxion’s Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions.

To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be accessed 15 minutes prior to the start of the live event.

To join the webcast, please click on this link. The webcast recording will be available on our website shortly after the event.

Contact information 
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai

About Evaxion
Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.

With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development.

We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.

For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website. 

Forward-looking statement 
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases